158 related articles for article (PubMed ID: 12554679)
1. ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway.
Wolvetang EJ; Wilson TJ; Sanij E; Busciglio J; Hatzistavrou T; Seth A; Hertzog PJ; Kola I
Hum Mol Genet; 2003 Feb; 12(3):247-55. PubMed ID: 12554679
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the chromosome 21 transcription factor Ets2 induces neuronal apoptosis.
Wolvetang EJ; Bradfield OM; Hatzistavrou T; Crack PJ; Busciglio J; Kola I; Hertzog PJ
Neurobiol Dis; 2003 Dec; 14(3):349-56. PubMed ID: 14678752
[TBL] [Abstract][Full Text] [Related]
3. The role of the Ets2 transcription factor in the proliferation, maturation, and survival of mouse thymocytes.
Zaldumbide A; Carlotti F; Pognonec P; Boulukos KE
J Immunol; 2002 Nov; 169(9):4873-81. PubMed ID: 12391198
[TBL] [Abstract][Full Text] [Related]
4. The chromosome 21 transcription factor ETS2 transactivates the beta-APP promoter: implications for Down syndrome.
Wolvetang EW; Bradfield OM; Tymms M; Zavarsek S; Hatzistavrou T; Kola I; Hertzog PJ
Biochim Biophys Acta; 2003 Jul; 1628(2):105-10. PubMed ID: 12890557
[TBL] [Abstract][Full Text] [Related]
5. Ets transcription factors and targets in osteogenesis.
Raouf A; Seth A
Oncogene; 2000 Dec; 19(55):6455-63. PubMed ID: 11175361
[TBL] [Abstract][Full Text] [Related]
6. Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice.
Sumarsono SH; Wilson TJ; Tymms MJ; Venter DJ; Corrick CM; Kola R; Lahoud MH; Papas TS; Seth A; Kola I
Nature; 1996 Feb; 379(6565):534-7. PubMed ID: 8596630
[TBL] [Abstract][Full Text] [Related]
7. ETS1 and ETS2 in p53 regulation: spatial separation of ETS binding sites (EBS) modulate protein: DNA interaction.
Venanzoni MC; Robinson LR; Hodge DR; Kola I; Seth A
Oncogene; 1996 Mar; 12(6):1199-1204. PubMed ID: 8649821
[TBL] [Abstract][Full Text] [Related]
8. Expression of the transcription factor ETS2 in brain of patients with Down syndrome--evidence against the overexpression-gene dosage hypothesis.
Greber-Platzer S; Schatzmann-Turhani D; Cairns N; Balcz B; Lubec G
J Neural Transm Suppl; 1999; 57():269-81. PubMed ID: 10666682
[TBL] [Abstract][Full Text] [Related]
9. Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness.
Foos G; Hauser CA
Oncogene; 2000 Nov; 19(48):5507-16. PubMed ID: 11114728
[TBL] [Abstract][Full Text] [Related]
10. Ets2 transcription factor inhibits mineralization and affects target gene expression during osteoblast maturation.
Li V; Raouf A; Kitching R; Seth A
In Vivo; 2004; 18(5):517-24. PubMed ID: 15523888
[TBL] [Abstract][Full Text] [Related]
11. Ets2 is not required for Ras or Neu/ErbB-2 mediated cellular transformation in vitro.
Hevér A; Oshima RG; Hauser CA
Exp Cell Res; 2003 Oct; 290(1):132-43. PubMed ID: 14516794
[TBL] [Abstract][Full Text] [Related]
12. The Ets2 transcription factor inhibits apoptosis induced by colony-stimulating factor 1 deprivation of macrophages through a Bcl-xL-dependent mechanism.
Sevilla L; Aperlo C; Dulic V; Chambard JC; Boutonnet C; Pasquier O; Pognonec P; Boulukos KE
Mol Cell Biol; 1999 Apr; 19(4):2624-34. PubMed ID: 10082528
[TBL] [Abstract][Full Text] [Related]
13. A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice.
Neznanov N; Man AK; Yamamoto H; Hauser CA; Cardiff RD; Oshima RG
Cancer Res; 1999 Sep; 59(17):4242-6. PubMed ID: 10485465
[TBL] [Abstract][Full Text] [Related]
14. TATA-less promoters of some Ets-family genes are efficiently repressed by wild-type p53.
Iotsova V; Crépieux P; Montpellier C; Laudet V; Stehelin D
Oncogene; 1996 Dec; 13(11):2331-7. PubMed ID: 8957074
[TBL] [Abstract][Full Text] [Related]
15. Bcl-XL expression correlates with primary macrophage differentiation, activation of functional competence, and survival and results from synergistic transcriptional activation by Ets2 and PU.1.
Sevilla L; Zaldumbide A; Carlotti F; Dayem MA; Pognonec P; Boulukos KE
J Biol Chem; 2001 May; 276(21):17800-7. PubMed ID: 11278399
[TBL] [Abstract][Full Text] [Related]
16. Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells.
Carbone GM; Napoli S; Valentini A; Cavalli F; Watson DK; Catapano CV
Nucleic Acids Res; 2004; 32(14):4358-67. PubMed ID: 15314206
[TBL] [Abstract][Full Text] [Related]
17. Ets-2 is induced by oxidative stress and sensitizes cells to H(2)O(2)-induced apoptosis: implications for Down's syndrome.
Sanij E; Hatzistavrou T; Hertzog P; Kola I; Wolvetang EJ
Biochem Biophys Res Commun; 2001 Oct; 287(4):1003-8. PubMed ID: 11573964
[TBL] [Abstract][Full Text] [Related]
18. Role of Ets2 in cyclic AMP regulation of the human chorionic gonadotropin beta promoter.
Johnson W; Jameson JL
Mol Cell Endocrinol; 2000 Jul; 165(1-2):17-24. PubMed ID: 10940479
[TBL] [Abstract][Full Text] [Related]
19. Ets2 and protein kinase C epsilon are important regulators of parathyroid hormone-related protein expression in MCF-7 breast cancer cells.
Lindemann RK; Braig M; Hauser CA; Nordheim A; Dittmer J
Biochem J; 2003 Jun; 372(Pt 3):787-97. PubMed ID: 12628005
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of transcription of the Ets2 gene in prostate cancer cells by a triplex-forming oligonucleotide.
Carbone GM; McGuffie EM; Collier A; Catapano CV
Nucleic Acids Res; 2003 Feb; 31(3):833-43. PubMed ID: 12560478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
